Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination |
| June 03, 2019 | June 2019 Bond Updates |
|
OSLO, Norway, June 3, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that a study showing abscopal effect of ONCOS-102 and Keytruda combination treatment in a... |
| View more at: https://www.prnewswire.com:443/news-releases/targovax-announces-publication-of-in-vivo-abscopal-effect-of-oncos-102-and-keytruda-combination-300860388.html |
| Related News |